Nxera Pharma Publishes its Annual and ESG Reports for the Year ended 31 December 2023
2024年6月18日 - 4:55PM
Tokyo, Japan and Cambridge, UK, 18 June 2024 –
Nxera Pharma (“Nxera” or “the Company”; TSE 4565), today announces
the publication of its Annual Report and its Environment, Social
& Governance (ESG) Report for the year ended 31 December
2023.
The Annual Report can be found by clicking
here.
The ESG Report can be found by clicking
here.
–END–
About Nxera Pharma Nxera
Pharma (formerly Sosei Heptares) is a technology powered biopharma
company, in pursuit of new specialty medicines to improve the lives
of patients with unmet needs in Japan and globally.
In addition to several products being
commercialized in Japan, we are advancing an extensive pipeline of
over 30 active programs from discovery through to late clinical
stage internally and in partnership with leading pharma and biotech
companies. This pipeline is focused on addressing major unmet needs
in some of the fastest-growing areas of medicine across neurology,
GI and immunology, metabolic disorders and rare diseases, and
leverages the power of our unique and industry leading
GPCR-targeted structure-based drug discovery NxWaveTM platform to
provide a sustainable source of best- or first-in-class
candidates.
Nxera employs over 350 talented people at key
locations in Tokyo and Osaka (Japan), London and Cambridge (UK),
Basel (Switzerland) and Seoul (South Korea) and is listed on the
Tokyo Stock Exchange (ticker: 4565).
For more information, please visit
www.nxera.life LinkedIn: @NxeraPharma | X: @NxeraPharma
| YouTube: @NxeraPharma
Enquiries:
Nxera – Media and Investor
Relations Kentaro Tahara, VP Investor Relations and
Corporate Strategy Shinichiro Nishishita, VP Investor
Relations, Head of Regulatory Disclosures Maya Bennison,
Communications Manager +81 (0)3 5210 3399 | +44 (0)1223 949390
|IR@Nxera.life
MEDiSTRAVA Consulting (for International
Media) Mark Swallow, Frazer Hall, Erica
Hollingsworth +44 (0)203 928 6900 |
Nxera@medistrava.com
Forward-looking
statements This press release contains
forward-looking statements, including statements about the
discovery, development, and commercialization of products. Various
risks may cause Nxera Pharma Group’s actual results to differ
materially from those expressed or implied by the forward looking
statements, including: adverse results in clinical development
programs; failure to obtain patent protection for inventions;
commercial limitations imposed by patents owned or controlled by
third parties; dependence upon strategic alliance partners to
develop and commercialize products and services; difficulties or
delays in obtaining regulatory approvals to market products and
services resulting from development efforts; the requirement for
substantial funding to conduct research and development and to
expand commercialization activities; and product initiatives by
competitors. As a result of these factors, prospective investors
are cautioned not to rely on any forward-looking statements. We
disclaim any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.